非小细胞肺癌脑转移的靶向和免疫治疗

Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, significantly affects the patients' quality of life.The prognosis of patients of NSCLC with brain metastasis is extremely poor, the average median survival is only 1 m-2 m without tr...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
肺癌脑转移专题
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972989/
https://www.ncbi.nlm.nih.gov/pubmed/27561803
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.08.08
Descripción
Sumario:Brain metastasis, a common complication of non-small cell lung cancer (NSCLC) with an incidence rate of 30%-50%, significantly affects the patients' quality of life.The prognosis of patients of NSCLC with brain metastasis is extremely poor, the average median survival is only 1 m-2 m without treatment.The targeted therapy based on lung cancer driven gene is a new treatment.Besides, the immunotherapy which can enhance the effect of anti-cancer by simulating the immune system is a new approach.The combination of targeted therapy and immunotherapy can greatly benefit patients in clinical work.

Ejemplares similares